Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials

PURPOSE: Clinical trials of statins and other lipid-lowering therapies (LLTs) often report large inter-individual variations in their effects on low-density lipoprotein cholesterol (LDL-C). We evaluated apparent hyporesponsiveness to the proprotein convertase subtilisin/kexin type 9 inhibitor aliroc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Drugs Ther
Main Authors: Bays, Harold E., Rosenson, Robert S., Baccara-Dinet, Marie T., Louie, Michael J., Thompson, Desmond, Hovingh, G. Kees
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5958153/
https://ncbi.nlm.nih.gov/pubmed/29627892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-018-6784-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados